Estimation of serum Copeptin (A novel marker of metabolic syndrome) in patients with type 2 diabetes mellitus

Abstract

Background: Copeptin , a neurohormone, has been identified lately as a biomarker for prediction of metabolic syndrome in recent few years. In this pilot study, we evaluated levels of Copeptin in patients of Type 2 Diabetes mellitus ( n =41). Materials and methods: The study was carried out on Type 2 Diabetes mellitus patients ( n =41) of either sex. The copeptin levels were estimated using Human C- Reactive protein ELISA Kit, For serum, plasma, cell culture supernatants and urine (Sigma Aldrich Co, LLC)Human Copeptin ELISA Kit (Mybiosource, Antibody. Protein. ELISA Kit). Results: We found that the levels of Copeptin ranged from 0.488 to 9.36 (median 1.18; mean 1.82) pmol/l in our cohort. There was no significant difference observed between Copeptin levels of patients with normal Body Mass Index (BMI) and those with higher than normal BMI. Conclusion: The present study reports for first time the values of Copeptin in Indian patients. However, there is need to estimate the levels in larger sample size to establish its utility and importance in Indian patients with metabolic syndrome.